Role of healthcare professionals in drug-drug interactions and clinical interventions
Abstract
Introduction and aim. Healthcare professionals including prescribers, pharmacists and nurses must have adequate knowledge of drug-drug interactions because they can cause toxicity, loss of efficacy, and side effects. This study was aimed to assess the respective roles of healthcare professionals in preventing drug-drug interactions by clinical interventions. Material and methods. This study was conducted at a Secondary Care Hospital of Pakistan in which total 1000 prescriptions were assessed for drug-drug interactions. Questionnaires and descriptive statistics were tools to assess the satisfaction of prescribers with pharmacists and their own prescribed medications before and after the clinical interventions. Modifications in medication therapies were done accordingly after the evaluation and acceptance of interventions. Results. The p-value was highly significant (p<0.05) which showed that the collaboration between healthcare professionals is necessary to avoid drug-drug interaction by clinical interventions. Acceptance rate of interventions was 77%. Clinical interventions are a useful tool in minimizing and preventing drug-drug interactions. The compliance of prescribers with their own prescribed medication regimens increased after clinical interventions. Conclusion. Prescribers, pharmacists and nurses have their respective roles in preventing drug-drug interactions and they must review the appropriateness of every medication order for clinical interventions.
Read the paper
Related studies
- Deciphering the Resistome of the Widespread Pseudomonas aeruginosa Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing
- Laboratory-based nationwide surveillance of antimicrobial resistance in Ghana
- Phenotypic characterization of an international Pseudomonas aeruginosa reference panel: strains of cystic fibrosis (CF) origin show less in vivo virulence than non-CF strains
- Incidence and factors associated with development of phlebitis: results of a pilot study cohort
- Efficacy of triple therapy with a proton pump inhibitor, levofloxacin, and amoxicillin as first-line treatment to eradicate Helicobacter pylori
- Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pyloriEradication in Taiwan
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.